Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Glass JL, Derkach A, Hilden P, King A, et al. Leuk Res 2021;106:106569.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Glass JL, Derkach A, Hilden P, King A, et al. Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Leuk Res 2021;106:106569.
PMID: 33857746